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Abstract
Renal tumor heterogeneity studies have utilized the von Hippel-Lindau VHL gene to classify disease into molecularly defined
subtypes to examine associations with etiologic risk factors and prognosis. The aim of this study was to provide a
comprehensive analysis of VHL inactivation in clear cell renal tumors (ccRCC) and to evaluate relationships between VHL
inactivation subgroups with renal cancer risk factors and VHL germline single nucleotide polymorphisms (SNPs). VHL genetic
and epigenetic inactivation was examined among 507 sporadic RCC/470 ccRCC cases using endonuclease scanning and
using bisulfite treatment and Sanger sequencing across 11 CpG sites within the VHL promoter. Case-only multivariate
analyses were conducted to identify associations between alteration subtypes and risk factors. VHL inactivation, either
through sequence alterations or promoter methylation in tumor DNA, was observed among 86.6% of ccRCC cases. Germline
VHL SNPs and a haplotype were associated with promoter hypermethylation in tumor tissue (OR=6.10; 95% CI: 2.28–16.35,
p=3.76E-4, p-global=8E-5). Risk of having genetic VHL inactivation was inversely associated with smoking due to a higher
proportion of wild-type ccRCC tumors [former: OR=0.70 (0.20–1.31) and current: OR=0.56 (0.32–0.99); P-trend=0.04].
Alteration prevalence did not differ by histopathologic characteristics or occupational exposure to trichloroethylene. ccRCC
cases with particular VHL germline polymorphisms were more likely to have VHL inactivation through promoter
hypermethylation than through sequence alterations in tumor DNA, suggesting that the presence of these SNPs may
represent an example of facilitated epigenetic variation (an inherited propensity towards epigenetic variation) in renal
tissue. A proportion of tumors from current smokers lacked VHL alterations and may represent a biologically distinct clinical
entity from inactivated cases.
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Introduction
Von Hippel-Lindau (VHL) alteration leading to protein
inactivation is considered a frequent, early event in renal
carcinogenesis that can be used as a biomarker of tumor
heterogeneity, to strengthen etiologic relationships with risk
factors, and study mechanistic pathways of disease [1–4]. The
most common established risk factors that are associated with
approximately 50% of renal cell cancer (RCC) cases include
obesity, hypertension, and tobacco smoking. Less-established risk
factors include occupational exposure to pesticides and the organic
solvent trichloroethylene (TCE). Dietary intake of vegetables and
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intake of red meat and milk products have been associated with
increased RCC risk, although not consistently [5]. Common
genetic variation has also been shown to modify RCC risk [5].
GermlinesequencealterationsoftheVHLgene were first identified
and have been observed in almost all families with VHL disease, a
hereditary cancer syndrome in which affected individuals are at risk
for renal cysts and clear cell RCC (ccRCC) [1]. In sporadic ccRCC,
alterations in the VHL gene have been reported in up to 91% of case
tumors [6]. The VHL gene plays a role in tissue-specific responses to
oxygen concentration and delivery. Under normal oxygen condi-
tions, the VHL protein forms a complex with elongin B, elongin C,
and cullin 2 which targets hydroxylated hypoxia inducible factor-
alpha (HIFa) for ubiquitin-mediated degradation [7,8]. Under
hypoxic conditions, the VHL complex cannot bind HIFa for
degradation because it is in the non-hydroxylated form. Therefore,
HIFa accumulates, resulting in transcription of additional genes that
facilitate oxygen delivery, cellular adaptation to oxygen deprivation,
and angiogenesis. Similarly, alteration of the VHL gene prevents
formation of the protein complex required for HIF degradation,
resulting in an excess of HIF and a similar gene expression pattern as
that observed under hypoxic conditions.
Recently, we applied sensitive and high-throughput mutation
detection methods in a pilot study of 205 well-characterized
sporadic ccRCC cases to comprehensively evaluate tumor DNA
for VHL sequence alterations and promoter methylation, and to
identify associations between the prevalence, type, and location of
VHL alterations with etiologic and clinical factors [6]. In the
current study, we expand upon our previous analysis [6], and
report findings from the entire case series of 507 sporadic RCC
cases, including 470 ccRCC patients. The combined dataset has
increased statistical power to identify associations between risk
factors and heterogeneous subgroups of cases defined by the type
of VHL alterations. Using questionnaire data on patient charac-
teristics, nutritional intake, and occupational exposures known or
suspected to modify risk, we attempted to replicate findings from
previously published studies in which evidence of tumor
heterogeneity had been reported [9–13]. A previously reported
VHL polymorphism, rs779805 and epigenetic inactivation of the
VHL gene were examined among these cases using a tag SNPs
method that is routinely used in association studies. The VHL gene
locus was examined using highly correlated SNPs to comprehen-
sively evaluate common genetic variation across this gene region
and risk of developing a specific type of VHL alteration [14].
Results
Patient and Tumor Characteristics
In Table S1, sporadic RCC cases from the Central and Eastern
European Case-Control study (CEERCC) that were included in
this analysis are compared to cases not included in this analysis by
their personal/clinical characteristics, and risk factors that have
been previously associated with the prevalence of RCC or VHL
alterations in tumor tissue. Cases not included in this study were
those from whom we were unable to collect frozen tumor biopsy
material for analyses. Collection of frozen tissue was most
successful among cases from the Czech Republic than the other
study regions. This analysis also included more cases with high
body mass index (BMI), with a lower level of education, and
included more M0 compared to M1 cases compared to those not
included in this analysis. The distribution of other factors was
similar across groups.
VHL Alteration Prevalence in RCC and ccRCC Tumor DNA
The prevalence of having any VHL alteration (i.e. inactivating,
silent, and intronic mutations, and promoter hypermethylation)
was 83.0% among all RCC cases, 88.3% among the subset of
ccRCC cases, and 16.2% among non-ccRCC cases (Table 1). The
higher percentage observed in ccRCC compared to all RCC cases
was due to a greater proportion of cases with VHL inactivating
alterations and a lower proportion of wild type ccRCC cases [i.e.
cases without inactivating VHL gene alterations], that were
primarily observed among non-ccRCC cases. The overall
prevalence of VHL promoter hypermethylation was similar in
RCC, ccRCC, and non-ccRCC cases. Among all ccRCC cases,
the highest alteration prevalence was located at codon 117
(N=13). These included 5 deletions, 5 missense, 2 insertions, and
1 nonsense sequence alteration at Codon 65 had the second
highest sequence alteration prevalence (N=11), and included 6
missense, 4 nonsense, and one deletion (data not shown). Thirty
putative splice junction sequence alterations, (intronic variants
located within 3 bases of an exon) were observed. VHL promoter
epigenetic and genetic inactivation was mutually exclusive in all
tumors analyzed. Because VHL genetic alterations were rarely
observed among non-ccRCC cases, all additional analyses were
restricted to confirmed ccRCC cases.
Univariate Analysis of VHL Alteration Subtypes by Tumor
and Patient Characteristics in ccRCC
From the univariate analysis (Table S2), risk factors with a p-
value,0.20 were selected as adjustment variables in multivariate
analyses. In addition to sex, age, and country, variables remained
in models if their inclusion changed risk estimates by at least 10%.
High blood pressure (p=0.16), family history of cancer (p=0.12),
and fruit intake frequency (p=0.09), were inversely associated
with VHL promoter hypermethylation and were selected for initial
inclusion in multivariate models. In addition to smoking (p=0.05),
family history of cancer (p=0.10) and fruit intake (p=0.14) were
initially included the multivariate analysis of genetic inactivation
prevalence.
Author Summary
In a large case-series of 470 sporadic clear cell renal cancer
(ccRCC) cases, we examined von Hippel-Lindau (VHL)
inactivation as a biomarker of tumor heterogeneity.
Germline alterations of the VHL gene were identified and
have been found in most families with VHL disease, a
hereditary syndrome associated with ccRCC. In sporadic
disease, VHL alterations have been reported in up to 91%
of cases. Here, we observed a high prevalence of VHL
inactivation through both genetic and epigenetic mech-
anisms that were highly associated with ccRCC. VHL
inactivation through promoter hypermethylation in tu-
mors was associated with inherited polymorphisms
selected to capture common variation across the VHL
locus. A high-risk haplotype associated with promoter
hypermethylation in tumor DNA was identified. These
findings suggest that the presence of these polymor-
phisms and VHL promoter hypermethylation may repre-
sent an example of an inherited propensity toward
epigenetic variation and potential silencing of the VHL
gene in tumor tissue. This result could have translational
implications, as individuals with the high-risk haplotype
could be targeted for increased surveillance. Smokers had
a higher prevalence of tumors without detectable VHL
sequence alteration or epigenetic inactivation. Such
tumors may be biologically distinct and have demonstrat-
ed a poorer prognosis compared to VHL inactivated cases.
VHL Gene Inactivation in ccRCC Tumors
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inactivation was observed in exon 1 [from 43.4% to 11.8%,
p=0.02] and a higher prevalence was observed in exon 3 [from
25.4% to 52.9%, p=0.08]. Inactivating VHL alterations were
found in 9/12 (75%) patients with a self-reported family history of
kidney cancer; 8 case tumors had inactivating alterations, and 1
had a hypermethylated VHL promoter. Specifically, two cases had
deletions located at codons 137 and 180, two had insertions
located at codons 184 and 203, and four had missense mutations,
two A/G transitions at codons 120 and 147, one T/A transversion
at codon 158, and one C/A transversion at amino acid 65 which
resulted in a stop (ATG) codon (data not shown). Of the three VHL
wild type cases, one had an alteration within intron 2 (-11) that was
not considered as an inactivating alteration in this study.
Multivariate Analyses
In Table 2, Odds Ratios (OR) and 95% confidence intervals
(CI) estimated from multivariate models of risk factors and VHL
alteration prevalence among ccRCC case tumor DNAs are
presented. Only tobacco smoking and fruit intake, were signifi-
cantly associated with VHL genetic inactivation in tumor tissue,
and/or were required for adjustment. Tobacco smoking was
inversely associated with VHL genetic inactivation in ccRCC
tumors. The OR associated with having a ccRCC tumor with a
genetic VHL inactivating alteration decreased in a dose-dependent
manner among former [OR=0.70(0.20–1.31)] and current
smokers [OR=0.56(0.32–0.99)] compared to never smokers
(p-trend=0.04). The association in the adjusted analysis was very
similar to that observed in the univariate analysis as was the
association with fruit intake that was not statistically significant
(Table S2). The association with fruit intake and genetic
alterations in tumor DNA did not differ with respect to smoking
status. The lower prevalence of genetically inactivated cases
among current smokers was due to a higher prevalence of wild
type cases (,8%) (Table 2). Low fruit intake frequency was
associated with having a VHL promoter hypermethylated tumor
(p=0.02). Compared to cases with high fruit intake frequency, the
association with promoter hypermethylation increased in a dose-
Table 1. VHL gene alterations among histologically confirmed RCC, clear cell RCC, and non-clear cell RCC cases.
All RCC Cases (N=507) Clear Cell RCC (N=470) Non clear cell RCC (N=37)
VHL Status N % N % N %
Any Alteration 421 83.0% 415 88.3% 6 16.2%
Functional Alteration 368 72.6% 366 77.9% 2 5.4%
1 Alteration 352 69.4% 350 74.5% 2 5.4%
2 Alterations 14 2.8% 14 3.0% 0 0.0%
3 Alterations 2 0.4% 2 0.4% 0 0.0%
No Functional Genetic Alteration 139 27.4% 104 22.1% 35 94.6%
P25L 13 2.6% 12 2.6% 1 2.7%
Silent 13 2.6% 13 2.8% 0 0.0%
Precodon 54 3 0.6% 3 0.6% 0 0.0%
Methylated 44 8.7% 41 8.7% 3 8.1%
Total Alterations (N=386) Total Alterations (N=384) Total Alterations (N=2)
Type of Genetic Alteration N % N %
Deletion 146 37.8% 145 37.8% 1 50.0%
Insertion 62 16.1% 62 16.1% 0 0.0%
Missense 107 27.7% 107 27.9% 0 0.0%
Nonsense 39 10.1% 39 10.2% 0 0.0%
Splicing 31 8.0% 30 7.8% 1 50.0%
39 UTR 1 0.3% 1 0.3% 0 0.0%
Total 386 100.0% 384 100.0% 2 100.0%
Location N % N % N %
Exon 1 141 36.5% 141 36.7% 0 0.0%
Intron 1 8 2.1% 8 2.1% 0 0.0%
Exon 2 116 30.1% 115 29.9% 1 50.0%
Intron 2 21 5.4% 20 5.2% 1 50.0%
Exon 3 98 25.4% 98 25.5% 0 0.0%
Total 384 99.5% 382 99.5% 2 100.0%
RCC include clear cell, papillary, chromophobe cases. ccRCC includes clear cell, ccRCC with papillary features, and sarcomatoid differentiation.
Non ccRCC includes papillary and chromophobe RCC cases.
Any alteration group includes VHL inactivating and non-inactivating genetic alterations and promoter hypermethylation.
Non functional genetic alteration group includes subjects without VHL inactivating alterations.
Total number of mutation group lacks the location of two splices with unknown intron location.
doi:10.1371/journal.pgen.1002312.t001
VHL Gene Inactivation in ccRCC Tumors
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3.03)] and low fruit intake [OR=3.03(1.16–8.33); p-trend=0.02].
After stratification by smoking status (ever/never), the association
between fruit intake and promoter hypermethylation was observed
among smokers when the high intake group was used as a referent
[medium: OR=1.72(0.59–3.13), and low: OR=4.35(1.09–16.67);
p-trend=0.03]. A significant trend was not observed among never
smokers (p-trend=0.59), however, the formal test for heterogene-
ity between models was not statistically significant (p-interac-
tion=0.28). In contrast, tumor histopathologic factors that are
generally associated with disease progression (i.e. stage, nuclear
grade, node positivity, metastases) were not associated with
alteration prevalence. Likewise, occupational exposure to the
solvent TCE was not associated with VHL alteration prevalence in
tumor DNA, when compared to unexposed cases.
In Table 3, the association between chromosome 3p loss and
specifically the 3p clone CTB110j24, which harbors the VHL gene
locus, were analyzed with respect to VHL gene inactivation
through either epigenetic or sequence alterations. The proportion
of both chromosome 3p loss, and loss of clone CTB110j24 were
significantly higher among cases with VHL gene inactivation
compared to cases without VHL inactivation (92.4%/93.9% vs
70.2%/61.7%; p,0.00001). Visual examination of each array
CGH profile among cases without and with VHL inactivation but
for whom chromosome 3p loss was observed, did not differ with
respect to loss of clone CTB110j24, and did not support the
hypothesis that biallelic loss of the VHL locus had occurred among
cases without VHL inactivation (i.e. wild type cases). In adjusted
multivariate analysis, the only factor that was significantly
associated with chromosome 3p loss was having a VHL gene
alteration, and the association was highly significant (OR=1250;
95% CI:476–3125, p,0.00001). Additional analysis of array
CGH data did not indicate that loss of chromosome 3p or clone
CTB110j24 differed significantly in tumor DNA from never
(92.1%), former (91.3%), or current smoking cases (92.3%), nor
did we observe a significant trend with tobacco exposure (data not
shown).
Germline VHL Polymorphisms and VHL Promoter
Hypermethylation in Tumor Tissue DNA
In Table 4, associations between germline VHL tag SNPs and
VHL gene promoter hypermethylation in tumor tissue were
evaluated in an attempt to replicate a previously reported
association between the presence of VHL SNP rs779805
(Ex1+19G.A) in germline DNA, and the prevalence of promoter
hypermethylation in tumor DNA [15]. A tag-SNP method was
used that relies upon linkage disequilibrium (LD) of highly
correlated SNPs to identify gene regions that could be associated
with disease susceptibility, or heterogeneous subgroups of cases
[14]. A significant association was observed between cases with
Table 2. Multivariate analysis of VHL inactivating alterations and ccRCC risk factors.
Patient Characteristics Subgroup
Number of Cases with/without
alteration OR-adj (95% CI) p-value
Inactivating Genetic Alterations
Tobacco Smoking Never 172/39 1.00 Ref
Former 82/24 0.70 (0.37–1.31) 0.26
Current 110/41 0.56 (0.32–0.99) 0.05
p-trend 0.04
Ever 0.60 (0.35–1.02) 0.06
Tertile Fruit Intake High 121/30 1.00 Ref
Medium 133/34 0.96 (0.53–1.74) 0.90
Low 96/36 0.60 (0.33–1.10) 0.10
p-trend 0.77 (0.57–1.05) 0.09
Promoter Hypermethylation
Tertile Fruit Intake High 15/108 1.00 Ref
Medium 17/137 1.37 (0.62–3.03) 0.44
Low 8/125 3.03 (1.16–8.33) 0.02
p-trend 0.02
Tertile Fruit Intake HIgh 5/61 1.00 Ref
Never Smokers Medium 7/61 0.92 (0.27–3.13) 0.89
Low 5/47 1.41 (0.38–5.26) 0.61
p-trend 0.59
Tertile Fruit Intake High 3/64 1.00 Ref
Ever Smokers Medium 10/76 1.72 (0.60–5.00) 0.32
Low 10/61 4.35 (1.09–16.67) 0.04
p-trend 0.03
Tobacco Smoking analyses adjusted for age, sex, country, tertile of fruit frequency intake.
Fruit intake analyses adjusted for age, sex, country and smoking status (ever, never).
Analyses of fruit intake stratified by smoking status are adjusted for age, sex, country.
Inactivating genetic alterations: cases with deletions, insertions, missense, nonsense, splice site alterations.
doi:10.1371/journal.pgen.1002312.t002
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additional tag SNPs across the VHL gene region. Some
associations between SNPs in germline and promoter hyper-
methylation in tumor DNA were stronger when analyses were
restricted to ccRCC cases. Significant trends were observed in
ccRCC cases that had germline minor alleles at VHL SNPs
rs265318 (22872 A.G), rs779805 (Ex1 +19 G.A), rs779812
(IVS1 21184 G.A), rs1678607 (IVS2 +108 T.G), rs1642742
(Ex3 +473 G.A), rs1642739 (3835 bp 39ST), and rs457414
(IRAK2 23754 A.C). Examination of this region using Haploview
revealed that some tag SNPs were highly correlated (Figure 1). To
identify regional associations between germline variants with
promoter hypermethylation in tumor DNA, a sliding window
analysis was conducted with a fixed window size ranging from 2 to
9 consecutive SNPs. The most significant global association across
all inherited haplotype variants and tumor-specific VHL promoter
hypermethylation was observed when a 9-SNP window spanning
across the entire VHL gene region was evaluated. This window
spanned from tag SNP rs6442154 (c3orf10, Ex3 290, T.C)
through rs457414 (IRAK2 23754 A.C) (p-global=8E-5). When
specific VHL haplotypes were evaluated individually and com-
pared to the common 9-SNP referent haplotype T-A-A-A-G-G-A-
C-A, two germline haplotypes were significantly associated with
tumor-specific promoter hypermethylation, specifically T-A-C-G-
A-T-G-A-C (OR=6.10; 95% CI:2.28–16.35, p=3.76E-4) and C-
G-A-G-G-G-G-C-A (OR=4.65; 95% CI:1.75–12.32; p=2.21E-
3, respectively). A similar association was observed with a 4-SNP
haplotype, as rs779805 was able capture common variation across
a highly correlated 6-SNP block, spanning from rs779805 through
rs457414. Haplotype analyses spanning a 3-SNP sliding window,
conducted to capture smaller regional variations, suggested that
two regions may be driving the association observed, one centered
within the VHL promoter at rs265318 (p=0.005) and the other
located 39 of the VHL stop codon centered at rs457414
(p=0.0004) (data not shown). No associations were observed
between these inherited polymorphisms and ccRCC cases with
genetically inactivated VHL or wild type tumors.
Discussion
The prevalence of VHL inactivation in ccRCC tumor DNA
from this large well-characterized case-series of sporadic RCC is
one of the highest reported in the literature, and is consistent with
recent publications including our previous report [6,9,13,15,16].
As in our previous study, VHL inactivation in ccRCC tumors
occurred either through genetic or epigenetic mechanisms.
Notably, VHL alteration prevalence was associated uniquely with
etiologic risk modifiers such as tobacco use, fruit intake, and VHL
tag SNPs that were examined to capture common germline
genetic variation across this region. We observed a slightly higher
prevalence of tumors without genetic or epigenetic inactivation of
VHL gene among current and former smokers, compared to never
smokers. The addition of array CGH analysis of this same case-
series of chromosome 3p loss and specifically the clone that
harbors the VHL locus, clone CTB110j24, enabled us to evaluate
the VHL gene region for evidence of biallelic loss among cases in
which we did not detect sequence alterations or evidence of
epigenetic inactivation. Multivariate analysis of chromosome 3p
loss revealed that the only patient/tumor characteristic or RCC
risk factor associated with 3p or clone CTB110j24 loss was
inactivation of the VHL gene, and the association was highly
significant. In addition, statistically significant associations between
VHL promoter hypermethylation and low fruit intake frequency
were observed, particularly in tumor DNA from smokers.
Interestingly, associations were observed with several tag SNPs
spanning the VHL gene in germline DNA and tumor-specific VHL
promoter hypermethylation. Of the ten tag SNPs selected to
capture common genetic variation across the VHL gene region and
evaluate associations with heterogeneous case subgroups, seven
were significantly associated with VHL promoter hypermethylation
in tumors. Analysis of haplotypes revealed the strongest association
was observed using a 9-SNP sliding window that spanned across
the entire VHL gene region. Lastly, we did not observe an
increased prevalence of inactivating alterations, multiple muta-
tions, nor a specific ‘‘hot spot’’ among TCE exposed cases,
compared to unexposed cases.
The association between inherited VHL polymorphisms and
promoter hypermethylation in sporadic ccRCC case tumor DNA
observed in the current study was similar to a previous report of 97
sporadic RCC cases [15] in which germline SNP rs779805 (Ex1
+19 A.G) was significantly associated with tumor-specific VHL
promoter hypermethylation. In the current study, along with
rs779805, nine additional SNPs were selected to capture (tag)
common variation across the VHL gene region to evaluate
associations with heterogeneous subgroups of cases. The global
p-values indicated that germline variation across the VHL gene
region was significantly associated with risk of having a VHL
hypermethylated tumor. When compared to the most common
SNP or haplotype as a common referent, subsequent analyses
revealed that several individual SNPs and two high risk haplotypes
Table 3. Cases with/without VHL genetic or epigenetic inactivation and chromosome 3p and VHL locus loss (clone CTB-110j24)
using array CGH.
Cases without
VHL inactivation
in tumor DNA (%)
Proportion
of cases
Case with VHL
gene inactivation
in tumor DNA (%)
Proportion
of cases
Total
number
of cases p-value
3p loss
No 14 3.4 29.8 28 6.7 7.6
Yes 33 8.0 70.2 340 81.9 92.4 415 p,0.00001
CTB110j24
No 18 4.4 38.3 22 5.3 6.1
Yes 29 7.0 61.7 340 83.1 93.9 409 p,0.00001
Cases without VHL inactivation Include those without genetic (sequence alterations) or epigenetic (promoter hypermethylation) of VHL in tumor DNA.
p-values adjusted for center, age, sex.
Comparative genomic hybridization (CGH).
doi:10.1371/journal.pgen.1002312.t003
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from ccRCC cases.
Clear Cell RCC Cases
Gene db SNP Location Base Change Unmethylated (%) Methylated (%) Odds Ratio ccRCC (95% CI) p-value
c3orf10 rs6442154 Ex3 290 TT 236 80.3 22 68.8 REF
CT 56 19.1 8 25.0 1.58 (0.62–4.04) 0.34
CC 2 0.7 2 6.3 10.10 (1.17–86.6) 0.03
Per allele-p-trend 2.08 (1.00–4.39) 0.05
CT+CC 58 19.8 10 31.3 1.92 (0.80–4.60) 0.14
VHL rs6796538 25011 A.G AA 176 59.9 13 41.9 REF
AG 105 35.7 16 51.6 1.84 (0.82–4.15) 0.14
GG 13 4.4 2 6.5 1.97 ((0.37–10.5) 0.43
Per allele-p-trend 1.61 (0.86–3.01) 0.14
AG+GG 118 40.1 18 58.1 1.86 (0.85–4.07) 0.12
VHL rs265318 22872 A.C AA 243 83.2 22 68.8 REF
AC 48 16.4 9 28.1 2.74 (1.12–6.74) 0.03
CC 1 0.3 1 3.1 31.33 (1.30–756.9) 0.03
Per allele-p-trend 3.20 (1.43–7.15) 0.004
AC+CC 49 16.7 10 31.2 3.08 (1.29–7.37) 0.01
VHL rs779805 Ex1 +19 G.A AA 149 50.5 12 37.5 REF
AG 131 44.4 13 40.6 1.17 (0.48–2.81) 0.73
GG 15 5.1 7 21.9 6.04 (1.93–18.9) 0.002
Per allele-p-trend 2.10 (1.16–3.79) 0.01
AG+GG 146 49.5 20 62.5 1.71 (0.77–3.79) 0.19
VHL rs779812 IVS1 21184 GG 240 81.6 22 68.8 REF
AG 52 17.7 9 28.1 2.58 (1.06–6.37) 0.04
AA 2 0.7 1 3.1 6.60 (0.45–96.3) 0.17
Per allele-p-trend 2.58 (1.19–5.58) 0.01
AG+AA 54 18.4 10 31.2 2.76 (1.16–6.65) 0.02
VHL rs1678607 IVS2 +108T.G GG 240 81.9 22 68.8 REF
GT 51 17.4 9 28.1 2.58 (1.06–6.30) 0.04
TT 2 0.7 1 3.1 6.61 (0.45–97.6) 0.17
Per allele-p-trend 2.58 (1.19–5.57) 0.02
GT+TT 53 18.1 10 31.2 2.76 (1.16–6.53) 0.02
VHL rs1642742 Ex3 +473 G.A AA 143 48.8 13 40.6 REF
AG 124 42.3 12 37.5 1.26 (0.52–3.07) 0.61
GG 26 8.9 7 21.9 4.68 (1.52–14.4) 0.007
Per allele-p-trend 1.97 (1.10–3.50) 0.02
AG+GG 150 51.2 19 59.4 1.75 (0.78–3.90) 0.17
VHL rs1642739 3835 bp 39ST CC 231 80.8 21 67.7 REF
AC 52 18.2 9 29.0 2.59 (1.05–6.41) 0.04
AA 3 1.1 1 3.2 3.49 (0.30–40.3) 0.32
Per allele-p-trend 2.30 (1.09–4.88) 0.03
AC+AA 55 19.3 10 32.2 2.66 (1.11–6.38) 0.03
IRAK2 rs457414 23754 A.C AA 144 49.0 10 31.3 REF
AC 125 42.5 15 46.9 2.05 (0.83–5.08) 0.12
CC 25 8.5 7 21.9 5.98 (1.87–19.2) 0.003
Per allele-p-trend 2.39 (1.33–4.30) 0.004
AC+CC 150 51.0 22 68.8 2.60 (1.11–6.09) 0.03
IRAK2 rs11465853 IVS1+249 G.C GG 131 44.9 9 28.1 REF
GC 118 40.4 17 53.1 2.52 (1.02–6.22) 0.05
CC 43 14.7 6 18.8 2.28 (0.69–7.60) 0.18
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tion. These findings are similar to several reports of other cancer
types, in which associations between constitutional (germline)
mutations were associated with gene specific hypermethylation
and silencing in tumors. In one report, a MGMT germline
polymorphism (rs16906252 C.T) located within the transcrip-
tional enhancer element of the MGMT promoter was strongly
associated with susceptibility to CpG island methylation and gene
silencing in colorectal cancer (OR=18.0; 95% CI:6.2–52.1,
p,.0001) [17,18]. Epigenetic silencing and transcriptional sup-
pression of the death associated protein kinase 1 gene DAPK1,a n
underlying factor in familial B cell chronic lymphocytic leukemia,
was found to be attributable to a germline SNP [c.1–6531 A.G]
located upstream of the DAPK1 promoter. Presence of this SNP
resulted in higher binding affinity for the HOXB7 protein [19].
Similarly, hypermethylation of the MLH1 and MLH2 genes, also
referred to as ‘‘epimutations’’ in inherited cases, have been
associated with germline variants in some cases [20,21]. In
contrast, in Beckwith-Wiedemann syndrome, an IGF2 gene
polymorphism has been associated with loss of imprinting of the
maternal allele-specific methylation of the KCNQ1 gene [22]. The
association observed in the current study between particular
inherited VHL haplotypes and promoter hypermethylation in
renal tumors may be an example of facilitated epigenetic variation,
or an increased inherited propensity towards epigenetic variation
with respect to a particular genotype [23]. Because we did not
analyze VHL promoter hypermethylation in germline DNA (or in
normal somatic tissues), it is unknown whether this particular
finding is an example of an epimutation, however additional
studies are warranted. This observation could be important for
future translational research, as identification of individuals with
high risk haplotypes could benefit from increased surveillance.
Also of note, haplotype analyses spanning a 3-SNP sliding window
across the VHL gene suggested that two regions may be driving the
association observed, one centered within the VHL promoter and
the other located 39 of the VHL stop codon. The first region of
interest, which spanned the promoter region of the VHL gene,
raises the possibility that SNP variants in the promoter region
could directly influence gene expression [24]. The second region
associated with promoter hypermethylation in tumor DNA was
centered 39 to the VHL stop codon. It is possible that this region
could be in linkage disequilibrium with a cis-acting structural or
copy number alteration that might permit a mechanistic
explanation to the associations observed [25].
VHL inactivation in tumor tissue was not associated with any of
the clinical parameters examined that are normally considered to
reflect disease progression such as stage, grade, and the presence
of metastases or positive lymph nodes. The lack of an association
between VHL alteration prevalence and indicators of tumor
progression was similar to some previous reports [26–31].
However, this finding was in contrast to our previous report of
205 sporadic cases [6], and a recent study (analyzing 177 patient
tumors) that reported an association between VHL promoter
hypermethylation and tumor grade [13]. The mutational
spectrum observed in our study was similar to others reporting
that the majority of genetic alterations in RCC were located in
exon 1 (codons 54–114) (an excellent summary of recent studies is
provided in ref 13). The prevalence of promoter hypermethyla-
tion observed among cases in our study was within the range
observed in other studies (,5–15%), and was lower than that
observed in a recent large study (a prevalence of 31% compared
to ,9% in our study) [13]. Unlike Young et al., [13] we did not
observe a difference in the prevalence of alterations between
tumors from male and female cases. These dissimilarities could be
partially explained by differences in the laboratory methods used
to detect promoter hypermethylation and/or the case selection
criteria used in each study. Our case series came from a hospital-
based case-control study that attempted to include all cases
diagnosed at hospitals serving a specific geographic region per
study center, and therefore may be more representative of the
general study population of sporadic cases than those acquired
through studies that uniquely include cases from tertiary care
centers.
We observed a higher prevalence (,8%) of VHL wild type cases
among current smokers compared to never smokers in this study.
The higher prevalence of VHL wild type cases among smokers had
been previously observed in our study of 205 cases but was not
statistically significant (p=0.07). A Dutch study also observed
more VHL wild type tumors among smokers [16]. A Swedish study
did not observe more VHL wild type tumors among smokers
overall, however, they observed that smoking modified the
associations observed between VHL alteration prevalence and
citrus fruit and vegetable intake [9]. Unlike the Swedish study, we
observed an association between VHL promoter hypermethylation
and low fruit intake frequency among smokers, rather than genetic
alteration prevalence. One reason for these differences may be the
use of formalin fixed tissues in both studies, compared to the use of
frozen tissue in the current study.
The 8% difference in the prevalence of VHL wild type tumors
among current smokers compared to never smokers could be
clinically meaningful as this subgroup is considered biologically
distinct from those with an inactivated VHL protein. Molecular
studies have shown that VHL wild type and VHL inactivated
tumors demonstrate differential signaling pathways [32–35] and
methylation profiles [36]. Clinical studies have reported mixed
results with respect to disease progression and survival. VHL wild
type tumors have shown reduced treatment response rates [37]
and lower median progression free survival [35]. In contrast, other
studies have reported that cases without VHL alterations had
better cancer-free and overall survival [34,35,37–41], with the
exception of Stage IV disease, as found in one study [39].
However, two studies reported no differences [13,27]. Clearly,
elucidation of the association between heterogeneous tumor
subtypes with respect to progression and survival warrants further
Clear Cell RCC Cases
Gene db SNP Location Base Change Unmethylated (%) Methylated (%) Odds Ratio ccRCC (95% CI) p-value
Per allele-p-trend 1.62 (0.94–2.77) 0.08
GC+CC 161 55.1 23 71.9 2.46 (1.04–5.84) 0.04
Odds ratios are adjusted for age, sex, country, and tertile of fruit frequency intake.
doi:10.1371/journal.pgen.1002312.t004
Table 4. Cont.
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across studies. Follow-up of cases in the current study is ongoing.
Occupational exposure to TCE was associated with an
increased risk of RCC in this case-control study [42], however
we were unable to replicate previous findings from a German
study of exposed workers in which a higher VHL mutation
prevalence and a hotspot located at nt454 (codon 81) was reported
[11]. In the current study, only one unexposed case had a VHL
mutation located at this location and the VHL mutation prevalence
was similar in TCE exposed and unexposed cases. Although the
German study result may have been a false-positive finding due to
small sample size, it was unlikely that mutations were caused by
Figure 1. Risk of VHL promoter hypermethylation associated with inherited VHL gene polymorphisms. A haploview plot showing the
correlation (r2) between the VHL SNPs genotyped. The number in each square represents the value of pair wise r
2 between any two markers.
doi:10.1371/journal.pgen.1002312.g001
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sample was analyzed in duplicate [11]. Another possibility was
that the German workers may have been exposed to higher TCE
levels than those in the current study. A second study of RCC
tumor heterogeneity recently conducted among TCE-exposed
workers in France, also did not replicate the high mutation
prevalence and hotspot observed in tumors from the German
exposed workers [43]. However, the French study reported an
unusually low VHL alteration prevalence overall, which may have
been due to the sensitivity of the laboratory methods applied and
the use of DNA extracted from formalin fixed rather than frozen
tumor material, as frozen tissue generally results in higher yields of
good quality DNA. Both differences could cause misclassification
of cases by their alteration status which would have biased results
toward the null.
Strengths of the current study include a large sample size, a high
participation rate, histological confirmation of all cases and also
the tumor tissue used for DNA extraction. The study also included
a high number of subjects from most case centers. We applied
accurate and sensitive, mutation detection methods in a large
study of well-characterized RCC and ccRCC cases to provide a
clear picture of VHL inactivation through sequence alteration and
promoter hypermethylation in a study conducted in a region with
the highest incidence of RCC world-wide [44]. CGH analysis of
chromosome 3p and specifically the clone harboring the VHL
locus enabled us to evaluate the VHL region for biallelic loss. The
multivariate analysis provided additional evidence to support that
the only patient characteristic or risk factor associated with 3p or
VHL locus loss was inactivation of the VHL gene through either
genetic or epigenetic mechanisms, and the association was highly
statistically significant. To our knowledge, this study is one of the
largest conducted to date. However, additional large studies, data
pooling, and meta-analyses will be required to clarify many of the
associations observed across study populations. Lastly, we did not
observe an increased risk associated with smoking in this case-
control study as would have been expected; however by
conducting case-only analyses, biases caused by control selection
were eliminated.
Some weaknesses of this study included misclassification of fruit,
vegetable, and alcohol intake frequency due to retrospective recall
using a limited 23-item food frequency questionnaire. There
may also have been misclassification of BMI and self-reported
hypertension among cases, as this information was collected post-
rather than prior to diagnosis. These qualities are strengths of the
ongoing Dutch cohort study. Lastly, the prevalence of VHL gene
epigenetic inactivation in tumor tissue was only about 9%.
Therefore, this analysis relied upon few cases that were both
heterozygous/homozygous for the VHL germline variants which
also had promoter hypermethylation in tumor tissue. This resulted
in unstable point estimates, and is reflected by some of the wide
confidence intervals observed.
In summary, this comprehensive analysis of 470 well-charac-
terized ccRCC patient tumor DNA samples observed VHL
inactivation through genetic or epigenetic mechanisms in 86.6%
of cases. The remaining 13.4% of cases in which we did not
observe evidence of VHL inactivation (VHL wild type cases) may
represent a biologically distinct subgroup, one that was observed
more frequently in tumor DNA from smokers than never-smokers.
Moreover, common germline VHL SNPs and haplotypes were
associated with promoter hypermethylation in RCC tumor tissue
and may demonstrate an example of facilitated epigenetic
variation with respect to inherited high risk genotypes [23]. These
findings show for the first time in a well-defined ccRCC case series
that somatic VHL gene alterations in tumors were uniquely
associated with exposures (i.e. tobacco smoking, diet) and inherited
VHL polymorphisms in germline DNA, rather than factors
associated with disease progression. Additional work is required
to elucidate the consequences in these VHL molecularly defined
subtypes in terms of etiology, biological mechanisms, treatment,
and survival.
Methods
Ethics Statement
The study protocol was approved by relevant ethics committees
and institutional review boards of all participating centers, the
International Agency for Research on Cancer (IARC), and the
U.S. National Cancer Institute (NCI) at the U.S. National
Institutes of Health. All study subjects and their physicians
provided written informed consent.
Study Population
Cases were from a hospital-based case-control study of
sporadic RCC that was conducted between 1999 and 2003 in
seven centers in four countries of Central and Eastern Europe
(Moscow, Russia; Bucharest, Romania; Lodz, Poland; and
Prague, Olomouc, Ceske-Budejovice, and Brno, Czech Republic)
as previously described [45,46]. All newly diagnosed and
histologically confirmed cases of sporadic kidney cancer (ICD-
O2 code C.64) were identified at participating hospitals in each
study region between 1999 and 2003. Histological slides of renal
tumor tissue from all cases were reviewed by an international
renal cancer pathology expert at the U.S. National Cancer
Institute for standardized confirmation and disease classification
(MM). Only confirmed cases of RCC and ccRCC were included
in the analyses. There were 1097 cases included in the final case-
control study: 524 of the 1097 cases (48%) originally diagnosed
with RCC from hospital reports that provided frozen tumor
biopsies for genetic analysis. Of the 524 cases, 507 (97%) cases
were confirmed with RCC by review of their biopsy material
provided, and 470 of the 507 (93%) were confirmed with the
ccRCC subtype.
Questionnaires were administered in person by trained
interviewers at each center. Subjects were asked about their
lifestyle habits, in particular tobacco consumption, anthropometric
measures one year before diagnosis, personal and familial medical
history, and dietary habits. Lifetime occupational information for
jobs of at least 12 months duration was also collected during
interviews through the use of general occupational and job-specific
questionnaires. Job-specific questionnaires covered (1) possible
organic and chlorinated solvent exposures, (2) hours per week of
solvent exposure, (3) source of solvent exposure, and (4) a
description of solvent use as previously described [42]. All coding
in the re-assessment was performed while blinded with respect to
the previous assessment (with respect to chlorinated solvents and
TCE exposures) as well as disease status.
Frequencies of fruit, vegetable, and alcohol intake were
examined as they have been inversely associated with the
prevalence of VHL alterations and particular alteration subtypes
[9]. The dietary questionnaire was comprised of 23 food items
which the study investigators selected by consensus during the
planning stage of the study, which had been validated as
previously described [47]. The questionnaire was repeated for
two different time periods: 1) the year prior to interview, and 2)
prior to political and market changes in 1989 (1991 in Russia). A
lifetime weighted average intake for the two time periods was
calculated as previously described [47].
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Frozen tumor biopsies were collected from a subset of cases
enrolled in the case-control study in which detailed information on
tumor pathology, patient characteristics, and occupational risk
factors for RCC, had been collected (Table S1). Tumor DNA
extraction was performed following an additional pathology
review of each tissue sample (FW) followed by macrodissection
to remove non-tumor tissue, as previously described [6]. Sample
areas estimated to contain at least 70% tumor cells were removed
for DNA extraction. For each sample, 5 mm
3 of tissue was
sectioned and digested with 0.4 mg Proteinase K per ml of digestion
buffer (500 mM KCl, 100 mM Tris-HCl, 15 mM MgCl2, 0.5%
Tween 20) at 50uC overnight. A standard protocol
1 was used to
extract DNA from the digested samples.
Analysis of VHL Sequence Alterations in Tumor DNA
PCR of VHL coding sequences, endonuclease scanning, and
sequencing were performed as previously described [6]. PCR
primers for this study for exons 1–3 were the following: VHL
Exon1- Forward:59-CTACGGAGGTCGACTCGGGAG, VHL
Exon 1- Reverse:59-GGGCTTCAGACCGTGCTATCG (ampli-
con length:495 bp); Exon 2- Forward:59-CCGTGCCCAGCCA-
CCGGTGTG, Exon 2- Reverse:59-GGATAACGTGCCTGA-
CATCAG (amplicon length:288 bp), Exon 3- Forward:59-CG-
TTCCTTGTACTGAGACCCTAG, Exon 3- Reverse:59-GAAC-
CAGTCCTGTATCTAGATCAAG (amplicon length:317 bp).
PCR
Amplification was carried out in 50 mL reactions using 10 to
15 ng tumor DNA and HotMaster Taq DNA Polymerase
(Eppendorf). Thermal cycling was accomplished using a MJ
Research (Bio-Rad) DNA Engine and a touchdown PCR program
with an annealing temperature of 58C. PCR products were
heteroduplexed using standard conditions. PCR products were
analyzed on 2% agarose gels and electrophoresis.
Endonuclease Scanning
Heteroduplexed PCR samples were analyzed using SURVEY-
OR Nuclease (Transgenomic, Inc.) and standard non-denaturing
HPLC conditions appropriate for DNA fragment sizing as
previously described [6]. A 100-bp DNA ladder (New England
Biolabs) was run as a size marker. Positive and negative controls
were included with each plate of PCR products to monitor
endonuclease cleavage efficiency.
Sequencing
Excess PCR primers were removed using the AMPure PCR
Purification system (Agencourt Bioscience Corp.). Reaction
chemistry using BigDye version 3.1 (Applied Biosystems) and
cycle sequencing on an MJ Research thermal cycler were adapted
from the manufacturer’s recommendations. Sequencing products
were purified using CleanSEQ reagents (Agencourt Bioscience).
Sequence chromatograms were analyzed using Sequencher
(GeneCodes, Ann Arbor, MI).
VHL Promoter Methylation
Standard methods were used for bisulfite modification of 100 to
500 ng of tumor DNA (Zymo Research Laboratories). Primers
were designed to amplify both methylated and unmethylated
alleles across 11 CpG dinucleotides of the VHL promoter. Primers
for the methylation analysis were the following: wild-type (WT)
amplicon: VHL WT-Forward-CTACGGAGGTCGACTCGG-
GAG, WT-Reverse-GCGATTGCAGAAGATGACCTG (ampli-
con length:335 bp); VHL nested primers: WT Forward-CG-
GGTGGTCTGGATCG, WT-Reverse AGTTCACCGAGCG-
CAGCA (nested amplicon length:226 bp). Post-bisulfite modifica-
tion primers that annealed to both methylated (M) and
unmethylated (U) alleles were as follows: VHL M/U Forward-59-
TTAYGGAGGTYGATTYGGGAG, and VHL M/U Reverse-
ACRATTACAAAAAATAACCTA, (amplicon length:335 bp),
nested primers VHL M/U Forward-YGGGTGGTTTGGATYG,
VHL M/U Reverse AATTCACCRAACRCAACA, nested (am-
plicon length: 226 bp). PCR was performed using an MJ Research
PTC200 thermal cycler and a touchdown PCR program with an
annealing temperature of 50uC. Nested PCR included 1 mLo fa
1:10 dilution of first-round product using cycling conditions as
described above. PCR products were visualized in 2.0% agarose
and bi-directionally sequenced. Cytosine positions in CpGs were
inspected for thymine or cytosine signals in chromatograms, and
scoring was conducted as follows: T only, not methylated; both
cytosine and thymine, partially methylated; C only, fully methyl-
ated. Tumor samples with at least four of 11 methylated CpGs
(.36%) were considered as hypermethylated. All analyses were run
in duplicate, blinded to VHL mutation status, and with positive
(CpGenome Universal Methylated DNA, Chemicon/Millipore)
and negative (K562 Human Genomic DNA, Promega) controls.
Array CGH
Each DNA sample from the same case-series was analyzed using
Scanning and OncoBAC arrays. Scanning arrays were comprised of
2464 BACs selected at approximately megabase intervals along the
genome as described previously [48,49]. OncoBAC arrays were
comprised of 960 Pa, PAC or BAC clones. About three-quarters of
the clones on the OncoBAC array sc o n t a i n e dg e n e sa n dS T S s
implicated in cancer development or progression. All cones were
printed in quadruplicate. DNA samples for array CGH were labeled
as described previously [48,49]. Briefly, 500 ng each of cancer and
normal female genomic DNA sample was labeled by random
priming with CY3- and CY5-dUTP, respectively; denatured; and
hybridized with unlabeled Cot-1 DNA to CGH arrays. After
hybridization, the slides were washed and imaged using a 16-bit
CCD camera through CY3, CY5, and DAPIfilters [50]. Array CGH
data image analyses were performed as described previously [51,52].
Tag SNP Analysis of Inherited VHL Polymorphisms
Genomic DNA was extracted from blood samples as described
previously [42]. Single nucleotide polymorphisms (SNPs) were
selected from the HapMap Project, using expected minor allele
frequencies reported among Caucasians, to capture 80–90% of
common genetic variation across the locus encompassing the VHL
gene, covering an average of 15 kb upstream and downstream of
the gene. This method relies upon linkage disequilibrium (LD) of
highly correlated SNPs in order to identify gene regions that are
associated with disease susceptibility, or in this case, specific
heterogeneous subgroups of cases defined by their VHL alteration
status [14]. SNPs selected (from 59 to 39 included the following:
rs6442154 (c3orf10, Ex3 290 T.C), rs6796538 (VHL, 25011
A.G), rs265318 (VHL, 22872 A.C), rs779805 (VHL, Ex1 +19
A.G), rs779812 (VHL, IVS1 21184 G.A), rs1678607 (VHL,
IVS2 +108 G.T), rs1642742 (VHL, Ex3 +473 A.G), rs1642739
(VHL 3835 bp 39STP C.A), rs457414 (IRAK2, 23754 A.C),
rs11465853 (IRAK2, IVS1 +249 G.C). Assays were validated at
the NCI Core Genotyping Facility (CGF) in 280 control samples
from the human diversity panel that included 76 African/African
Americans, 66 Caucasians, 49 Native Americans/Hispanics, and
89 Pacific Rim Asians. Subsequently, minor allele frequencies
(MAFs) were determined from the CGF panel among Caucasians.
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Methods for assays can be found at: http://snp500cancer.nci.nih.
gov. DNA samples were blinded and randomized on PCR plates
to avoid any potential bias and duplicate genotyping was
performed for a randomly selected 5% of the total series for
quality control. Concordance rates were .99% for all SNPs. All
SNPs analyzed were within the expected distributions of Hardy-
Weinberg equilibrium (p,0.05).
Statistical Analyses
Tumor and patient characteristics including clinical stage, Fuhr-
man nuclear grade (I–IV), node stage (N0, N1, N2–3), body mass
index (BMI) (,25, 25–35, .35), and smoking status were considered
as categorical variables. Smoking status (never, former, or current
smoker) was defined as status 2 years prior to the interview.
Specifically, participants who were smoking in the 24 months prior
interview were classified as current smokers. Other variables such as
metastasis (M0, M1) self-reported hypertension (no/yes), family
history of cancer or kidney cancer (no/yes), sex, and age at diagnosis
(,50,$50 years)wereanalyzedasdichotomousvariables.Additional
exposures and risk factors were selected based upon previous
published reports of renal tumor heterogeneity including our own
[6]. These additional factors included fruit, vegetable, and alcohol
intake frequency, and VHL tagging SNPs [9–13]. Because occupa-
tional trichloroethylene (TCE) exposure was positively associated
with RCC risk in this population [42] and because TCE exposure
had previously been associated with an increased prevalence of VHL
mutation among occupationally exposed workers [11,12], we also
evaluated associations between occupational exposure to organic and
chlorinated solvents and trichloroethylene with VHL alteration
prevalence. For nutritional variables, intake frequencies of related
foods were summed to form food group intake categories based on
tertile cutoff points that were defined by consumption frequency
among controls. Categories of consumption for food-specific items
were grouped as low (never to ,once per month), medium ($once
per month but ,once per week), and high ($once per week to daily).
Categories of alcohol consumption as grams per week of ethanol
among weekly drinkers were none, low (,36.5), medium (36.5–
137.5), and high $137.5) as described previously [47].
The prevalences of VHL genetic (sequence alterations) and
epigenetic alterations (promoter hypermethylation) observed in
tumor DNA samples were considered as dichotomous variables per
case (no/yes). VHL gene nonsynonymous sequence alterations were
considered as inactivating alterations if they were located within
exons 1–3 and would lead to an altered amino acid sequence or a
truncated VHL protein. Splice site mutations and promoter
hypermethylation were also considered as inactivating alterations.
DNA sequence alterations that were synonymous or SNPs were not
considered as inactivating alterations. Similarly, sequence alterations
that were located 59 of codon 54, which were very rare, were not
considered as inactivating alterations unless they were nonsynon-
ymous and also would cause an alteration in the coding sequence of
both pVHL19 and pVHL30 translation products. These included
alterations such as insertions, deletions, and nonsense mutations. As
in our previous study, the P25L variant was only considered an
inactivating alteration if the case also possessed a second VHL
alteration that would be considered inactivating using the above
criteria. The prevalence of cases with a particular type of alteration
was calculated by dividing the number of cases with that type of
alteration by the total number of cases analyzed in the group. Chi-
square tests were applied to contingency table (262) analyses to test
for differences between the proportion of cases with or without a
particular alteration subtype within each group. Trend tests were
used to analyze associations between categorical variables and cases
with particular types of alterations. Ordered logistic regression was
used for multivariate analyses to evaluate associations between
categorical variables and case subgroups, initially adjusting for
variables that were associated with the same alteration subtype in our
univariate analyses (p,0.20; Table S2). With the exception of sex,
age, and country, other variables remained in multivariate models if
their inclusion modified risk estimates by at least 10%.
For genotyping analyses, each SNP was assessed in three
categories, (G0=homozygote for the major allele, G1=heterozygote,
G2=homozygote for the minor allele) using the most common allele
as a referent. LD between SNPs was measured using Lewontin’s D’
statistic. Correlation (r
2) between tagged regions was evaluated in
Haploview. To evaluate associations between SNPs and VHL
promoter hypermethylation prevalence, logistic regression models
were used to calculate odds ratios (OR) and 95% confidence intervals
(CI), adjusting for sex, age, country, and fruit intake. Risks were
estimated using both additive and dominant models. Risk per allele
and trends were calculated using unconditional logistic regression.
Analyses were conducted using STATA 10.0 (Stata Corporation,
College Station, TX) and all statistical tests were two-sided.
Haplotype analysis was used to explore the combined
contribution of consecutive VHL tagging SNPs. A sliding window
analysis was first conducted in MatLab to identify regions of
interest (The MathWorks, Inc., Natick, MA). For the 10 SNPs
examined, sliding windows of 2–9 SNPs were evaluated,
accounting for multiple testing and correlations between SNPs.
The significance of haplotype-based associations was assessed
using the score test [53]. Haplotypes of interest were analyzed
using an R package Haplostats (Version 1.3.1) in (version 2.4.1)
adjusting for sex, age, and country. The most common haplotype
was used as the reference group and rare haplotypes with
frequencies of ,5% were combined into one group. Generalized
linear models accounting for phase ambiguity were used to
estimate haplotype-specific ORs per copy [54,55].
For array CGH analyses of these same cases, those with loss of
chromosome arm 3p or clone CTB110j24 to those without, the
presence of a loss was considered as a dependent variable in
stepwise logistic regression models to first evaluate associations
with clinical risk factors including: T stage (T1, T2, T3–4),
Fuhrman nuclear grade (1–2, 3–4), node positivity (N0, N1, N2–
3), and presence of metastases (M0, M1, Mx). In addition, co-
variates and etiologic risk factors (described above) that were
previously associated with RCC risk were initially analyzed using
univariate analyses, including the presence of a VHL inactivating
alteration in tumor tissue (no/yes-any). The criterion for initial
inclusion of a variable into multivariate models was a p-
value,0.20. Frequency matching variables inherent to the study
design (i.e. country, sex and age) were included into all of the
models regardless of associations with outcome. Variables selected
were then fitted in logistic models adjusted for sex, country, and
age, to obtain odds ratios (OR) and 95% confidence intervals (95%
CI) as estimates of risk for both types of alterations. All analyses
were conducted using SAS 9.1.3 software (SAS Institute Inc.) and
STATA 10.0 and statistical tests were two-sided.
Supporting Information
Table S1 Distribution of patient and ccRCC tumor characteris-
ticsamongcasesincludedandnotincludedinVHLalterationstudy.
(XLS)
Table S2 Univariate analysis of von Hippel-Lindau inactivating
alterations associated with patient descriptive and clinical
characteristics in clear cell RCC cases.
(XLS)
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